Undisclosed VRK1 inhibitor / Tango Therap - LARVOL DELTA

VRK1 inhibition leverages paralog synthetic lethality to selectively target VRK2-deficient cancer cells (AACR 2026) - "Furthermore, in vivo tolerability studies suggest that VRK1 inhibitors are well-tolerated in immunocompromised mice. Preclinical validation studies support the development of VRK1 inhibitors for the treatment of patients with VRK2-deficient tumors such as glioblastoma and neuroblastoma."

Synthetic lethality • Brain Cancer • Glioblastoma • Neuroblastoma • Oncology • Solid Tumor